Polaris Group
Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 20… Read more
Polaris Group - Asset Resilience Ratio
Polaris Group (6550) has an Asset Resilience Ratio of 10.81% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Polaris Group's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Polaris Group's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$884.39 Million | 10.81% |
| Total Liquid Assets | NT$884.39 Million | 10.81% |
Asset Resilience Insights
- Moderate Liquidity: Polaris Group has 10.81% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Polaris Group Industry Peers by Asset Resilience Ratio
Compare Polaris Group's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Polaris Group (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Polaris Group.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.95% | NT$1.18 Billion | NT$9.09 Billion | -1.70pp |
| 2023-12-31 | 14.65% | NT$1.33 Billion | NT$9.10 Billion | +12.96pp |
| 2022-12-31 | 1.69% | NT$155.99 Million | NT$9.22 Billion | -4.01pp |
| 2021-12-31 | 5.71% | NT$446.27 Million | NT$7.82 Billion | -44.94pp |
| 2020-12-31 | 50.64% | NT$1.70 Billion | NT$3.36 Billion | +50.40pp |
| 2019-12-31 | 0.24% | NT$9.87 Million | NT$4.11 Billion | -- |